We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
GSK plc | NYSE:GSK | NYSE | Depository Receipt |
Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.555 | 1.28% | 44.005 | 44.33 | 43.96 | 44.13 | 2,148,197 | 19:48:32 |
Trial Name
|
GSK ID/NCT ID
|
Status
|
Design
|
DREAMM-1
|
117159/
NCT02064387
|
Active,
not recruiting
|
A Phase
I Open-label Study to Investigate the Safety, Pharmacokinetics,
Pharmacodynamics, Immunogenicity and Clinical Activity of
Belantamab Mafodotin (GSK285791) in Subjects with
Relapsed/Refractory Multiple Myeloma and Other Advanced Hematologic
Malignancies Expressing BCMA
|
DREAMM-2
|
205678/NCT03525678
|
Active,
not recruiting
|
A Study
to Investigate the Efficacy and Safety of Two Doses of Belantamab
Mafodotin (GSK2857916) in Subjects with Relapsed/Refractory
Multiple Myeloma Who are Refractory to a Proteasome Inhibitor and
an Immunomodulatory Agent and Have Failed Prior Treatment with an
Anti-CD38 Antibody
|
DREAMM-3
|
207495
|
Planned
|
A Phase
III Open-Label, Randomized Study to Evaluate the Efficacy and
Safety of Belantamab Mafodotin (GSK2857916) Compared to
Pomalidomide plus low-dose Dexamethasone (Pom/Dex) in Participants
with Relapsed/Refractory Multiple Myeloma
|
DREAMM-4
|
205207/NCT03848845
|
Recruiting
|
A Phase
I/II Single Arm Open-Label Study to Explore Safety and Clinical
Activity of Belantamab Mafodotin (GSK2857916) Administered in
Combination with Pembrolizumab in Subjects with Relapsed/Refractory
Multiple Myeloma
|
DREAMM-5
|
208887
|
Planned
|
A Phase
I/II, Randomized, Open-label Platform Study of Belantamab Mafodotin
(GSK2857916) with Innovative Combination Anti-Cancer Treatments in
Participants with Relapsed/Refractory Multiple Myeloma
|
DREAMM-6
|
207497/NCT03544281
|
Recruiting
|
A Phase
I/II Randomized Study to Evaluate Safety, Tolerability and Clinical
Activity of Belantamab Mafodotin (GSK2857916) Administered in
Combination with Lenalidomide plus Dexamethasone (Arm A), or in
Combination with Bortezomib plus Dexamethasone (Arm B) in Subjects
with Relapsed/Refractory Multiple Myeloma
|
DREAMM-7
|
207503
|
Planned
|
A Phase
III Study of Belantamab Mafodotin (GSK2857916) Administered in
Combination with Bortezomib plus Dexamethasone versus Daratumumab,
Bortezomib, and Dexamethasone in participants with
relapsed/refractory multiple myeloma
|
DREAMM-8
|
207499
|
Planned
|
A Phase
III, Multicentre, Open-Label, Randomized Study to Evaluate the
Efficacy and Safety of Belantamab Mafodotin (GSK2857916) in
Combination with Pomalidomide plus Low-Dose Dexamethasone (BPd)
versus Pomalidomide plus Bortezomib and Low-Dose Dexamethasone
(PVd) in Participants with Relapsed/Refractory Multiple
Myeloma
|
DREAMM-9
|
209664
|
Planned
|
A Phase
III Study of Belantamab Mafodotin (GSK2857916) Administered in
Combination with Bortezomib plus Lenalidomide and Low-Dose
Dexamethasone (VRd) vs. VRd in Participants with Newly
Diagnosed Multiple Myeloma who are Ineligible for
Transplant
|
DREAMM-10
|
207500
|
Planned
|
A Phase
III Study of Belantamab Mafodotin (GSK2857916) Administered in
Combination with a Novel Agent versus SoC
|
ISS / GSK
Co-Sponsored Study
|
209418
|
Recruiting
|
A Phase
I/II Dose-escalation and Dose-expansion Study of Belantamab
Mafodotin (GSK2857916)Administered in Combination with
Pomalidomide plus Low-dose Dexamethasone in Patients
with Relapsed/Refractory Multiple Myeloma Who Have
Received Two or More Prior Lines of Therapy That Must Have Included
Lenalidomide and a Proteasome
Inhibitor
|
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: August
23, 2019
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions